| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cardiovascular Diseases | 19 | 2020 | 490 | 4.200 |
Why?
|
| Cysteine Endopeptidases | 42 | 2022 | 67 | 3.900 |
Why?
|
| Endopeptidases | 22 | 2017 | 66 | 3.800 |
Why?
|
| C-Reactive Protein | 19 | 2012 | 155 | 3.310 |
Why?
|
| Neoplasms | 20 | 2020 | 1325 | 3.060 |
Why?
|
| Ubiquitins | 27 | 2016 | 40 | 2.890 |
Why?
|
| Sumoylation | 18 | 2021 | 21 | 2.780 |
Why?
|
| Small Ubiquitin-Related Modifier Proteins | 14 | 2020 | 17 | 2.740 |
Why?
|
| Anthracyclines | 7 | 2025 | 32 | 2.440 |
Why?
|
| Myocytes, Cardiac | 7 | 2025 | 129 | 2.200 |
Why?
|
| SUMO-1 Protein | 22 | 2015 | 25 | 2.160 |
Why?
|
| Antineoplastic Agents | 11 | 2019 | 1222 | 2.000 |
Why?
|
| Myocardial Infarction | 12 | 2014 | 412 | 1.960 |
Why?
|
| Animals | 114 | 2025 | 13505 | 1.920 |
Why?
|
| Antibiotics, Antineoplastic | 3 | 2025 | 80 | 1.770 |
Why?
|
| Protein Processing, Post-Translational | 12 | 2020 | 153 | 1.630 |
Why?
|
| Heart Diseases | 4 | 2025 | 216 | 1.620 |
Why?
|
| Signal Transduction | 19 | 2025 | 1671 | 1.420 |
Why?
|
| Prostatic Neoplasms | 9 | 2017 | 398 | 1.410 |
Why?
|
| Mice | 64 | 2025 | 5949 | 1.400 |
Why?
|
| Humans | 141 | 2025 | 52483 | 1.290 |
Why?
|
| Arteriosclerosis | 11 | 2005 | 53 | 1.270 |
Why?
|
| TNF Receptor-Associated Factor 6 | 3 | 2025 | 8 | 1.140 |
Why?
|
| Apoptosis | 14 | 2018 | 1119 | 1.090 |
Why?
|
| Multienzyme Complexes | 5 | 2010 | 40 | 1.070 |
Why?
|
| T-Lymphocytes | 13 | 2012 | 340 | 1.040 |
Why?
|
| Nuclear Proteins | 11 | 2021 | 245 | 1.030 |
Why?
|
| Disease Management | 2 | 2017 | 188 | 1.020 |
Why?
|
| Transcription, Genetic | 12 | 2016 | 378 | 1.010 |
Why?
|
| Thrombosis | 6 | 2017 | 253 | 1.010 |
Why?
|
| Heart Failure | 9 | 2023 | 565 | 1.010 |
Why?
|
| Autoantigens | 3 | 2021 | 53 | 0.990 |
Why?
|
| Medical Oncology | 3 | 2019 | 104 | 0.970 |
Why?
|
| Toll-Like Receptor 4 | 2 | 2025 | 51 | 0.960 |
Why?
|
| Cell Cycle Proteins | 6 | 2021 | 169 | 0.930 |
Why?
|
| DNA Topoisomerases, Type II | 4 | 2025 | 18 | 0.930 |
Why?
|
| Transcription Factors | 16 | 2021 | 566 | 0.890 |
Why?
|
| Cardiotoxins | 3 | 2013 | 4 | 0.860 |
Why?
|
| Immunity, Innate | 3 | 2021 | 117 | 0.850 |
Why?
|
| Atherosclerosis | 7 | 2015 | 219 | 0.820 |
Why?
|
| Disease Models, Animal | 12 | 2023 | 1478 | 0.800 |
Why?
|
| Cardiology | 2 | 2016 | 97 | 0.790 |
Why?
|
| Inflammation Mediators | 4 | 2009 | 115 | 0.790 |
Why?
|
| Macrophages | 4 | 2021 | 379 | 0.780 |
Why?
|
| Toll-Like Receptors | 2 | 2021 | 27 | 0.780 |
Why?
|
| Heart | 5 | 2014 | 345 | 0.780 |
Why?
|
| Casein Kinase II | 1 | 2021 | 10 | 0.760 |
Why?
|
| DNA Repair | 3 | 2016 | 195 | 0.750 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2021 | 17 | 0.750 |
Why?
|
| Neoplasm Proteins | 8 | 2006 | 334 | 0.730 |
Why?
|
| Molecular Sequence Data | 24 | 2012 | 778 | 0.720 |
Why?
|
| Ligases | 6 | 2000 | 10 | 0.720 |
Why?
|
| Cells, Cultured | 21 | 2018 | 1567 | 0.700 |
Why?
|
| Peptide Hydrolases | 5 | 2018 | 63 | 0.700 |
Why?
|
| Tumor Necrosis Factor-alpha | 6 | 2006 | 399 | 0.680 |
Why?
|
| Muscle, Smooth, Vascular | 5 | 2004 | 133 | 0.680 |
Why?
|
| Endothelium, Vascular | 9 | 2013 | 246 | 0.680 |
Why?
|
| Antigens, CD34 | 5 | 2010 | 72 | 0.680 |
Why?
|
| Sepsis | 2 | 2025 | 239 | 0.660 |
Why?
|
| Amino Acid Sequence | 22 | 2018 | 578 | 0.660 |
Why?
|
| Doxorubicin | 3 | 2025 | 241 | 0.660 |
Why?
|
| Inflammation | 9 | 2018 | 641 | 0.650 |
Why?
|
| Vasculitis | 5 | 2015 | 29 | 0.620 |
Why?
|
| Saccharomyces cerevisiae Proteins | 6 | 2000 | 139 | 0.620 |
Why?
|
| Thromboembolism | 3 | 2017 | 52 | 0.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2019 | 1031 | 0.610 |
Why?
|
| Myocardium | 8 | 2021 | 453 | 0.600 |
Why?
|
| Glycosylphosphatidylinositols | 11 | 1994 | 31 | 0.590 |
Why?
|
| Hematopoietic Stem Cells | 4 | 2018 | 187 | 0.580 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 6 | 2012 | 59 | 0.570 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2017 | 55 | 0.530 |
Why?
|
| Vascular Diseases | 2 | 2008 | 76 | 0.530 |
Why?
|
| COS Cells | 15 | 2006 | 73 | 0.520 |
Why?
|
| Natriuretic Peptide, Brain | 2 | 2016 | 29 | 0.520 |
Why?
|
| DNA-Binding Proteins | 5 | 2013 | 422 | 0.520 |
Why?
|
| Cell Differentiation | 8 | 2012 | 665 | 0.520 |
Why?
|
| Retinoblastoma-Binding Protein 2 | 1 | 2016 | 6 | 0.510 |
Why?
|
| Origin Recognition Complex | 1 | 2016 | 6 | 0.510 |
Why?
|
| Cytokines | 5 | 2021 | 623 | 0.510 |
Why?
|
| Troponin I | 1 | 2016 | 18 | 0.500 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 184 | 0.500 |
Why?
|
| Receptors, Androgen | 2 | 2007 | 46 | 0.500 |
Why?
|
| Leukocytes, Mononuclear | 2 | 2014 | 123 | 0.490 |
Why?
|
| Genomic Instability | 1 | 2016 | 89 | 0.490 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 31 | 0.480 |
Why?
|
| Point-of-Care Systems | 1 | 2016 | 65 | 0.480 |
Why?
|
| Echocardiography, Three-Dimensional | 1 | 2015 | 15 | 0.480 |
Why?
|
| Adipocytes | 2 | 2007 | 132 | 0.480 |
Why?
|
| Mutation | 9 | 2011 | 1347 | 0.480 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 3 | 2007 | 39 | 0.470 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2005 | 145 | 0.460 |
Why?
|
| KCNQ Potassium Channels | 1 | 2014 | 3 | 0.460 |
Why?
|
| Death, Sudden | 1 | 2014 | 9 | 0.460 |
Why?
|
| Stress, Physiological | 2 | 2015 | 183 | 0.450 |
Why?
|
| Histones | 2 | 2016 | 314 | 0.450 |
Why?
|
| Mice, SCID | 8 | 2013 | 182 | 0.450 |
Why?
|
| B-Lymphocytes | 6 | 2012 | 184 | 0.450 |
Why?
|
| Survivors | 1 | 2015 | 120 | 0.440 |
Why?
|
| Gene Transfer Techniques | 1 | 2014 | 40 | 0.440 |
Why?
|
| Male | 32 | 2025 | 26761 | 0.440 |
Why?
|
| Mice, Knockout | 10 | 2018 | 879 | 0.440 |
Why?
|
| Neurons | 5 | 2023 | 418 | 0.440 |
Why?
|
| Seizures | 2 | 2021 | 208 | 0.430 |
Why?
|
| Endothelial Cells | 4 | 2013 | 262 | 0.430 |
Why?
|
| Gene Expression Regulation | 9 | 2014 | 990 | 0.430 |
Why?
|
| Mitochondrial Turnover | 2 | 2012 | 3 | 0.430 |
Why?
|
| Stem Cells | 4 | 2023 | 177 | 0.430 |
Why?
|
| Gene Targeting | 1 | 2013 | 31 | 0.420 |
Why?
|
| Mice, Transgenic | 6 | 2022 | 552 | 0.420 |
Why?
|
| Risk Factors | 12 | 2025 | 3889 | 0.420 |
Why?
|
| Cell Line | 18 | 2013 | 1030 | 0.420 |
Why?
|
| Primary Prevention | 1 | 2013 | 45 | 0.420 |
Why?
|
| Reactive Oxygen Species | 8 | 2018 | 421 | 0.420 |
Why?
|
| Lipopolysaccharides | 6 | 2025 | 206 | 0.410 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2014 | 57 | 0.410 |
Why?
|
| Intercellular Adhesion Molecule-1 | 4 | 2005 | 61 | 0.410 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 2 | 2010 | 8 | 0.410 |
Why?
|
| Nerve Tissue Proteins | 2 | 2008 | 187 | 0.410 |
Why?
|
| Energy Metabolism | 1 | 2015 | 302 | 0.400 |
Why?
|
| Receptors, CXCR4 | 1 | 2012 | 29 | 0.400 |
Why?
|
| Base Sequence | 15 | 2007 | 640 | 0.400 |
Why?
|
| Phosphatidylinositols | 7 | 1992 | 29 | 0.390 |
Why?
|
| Protein Binding | 15 | 2018 | 667 | 0.390 |
Why?
|
| Gene Silencing | 2 | 2010 | 118 | 0.390 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 2 | 2011 | 4 | 0.390 |
Why?
|
| Chemokine CXCL12 | 1 | 2012 | 32 | 0.390 |
Why?
|
| STAT5 Transcription Factor | 1 | 2012 | 10 | 0.380 |
Why?
|
| Sarcoplasmic Reticulum Calcium-Transporting ATPases | 1 | 2012 | 8 | 0.380 |
Why?
|
| Sequence Homology, Amino Acid | 9 | 2012 | 140 | 0.380 |
Why?
|
| Mitochondria | 6 | 2014 | 430 | 0.380 |
Why?
|
| KCNQ3 Potassium Channel | 2 | 2022 | 4 | 0.380 |
Why?
|
| Mice, Inbred C57BL | 12 | 2025 | 1884 | 0.380 |
Why?
|
| Hypertension | 4 | 2023 | 565 | 0.380 |
Why?
|
| Heparin | 1 | 2012 | 88 | 0.380 |
Why?
|
| KCNQ2 Potassium Channel | 2 | 2022 | 9 | 0.380 |
Why?
|
| Bone Marrow Cells | 1 | 2012 | 190 | 0.370 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 1 | 2011 | 19 | 0.370 |
Why?
|
| Germ-Line Mutation | 1 | 2011 | 66 | 0.370 |
Why?
|
| Ubiquitin | 4 | 2006 | 47 | 0.370 |
Why?
|
| Clinical Trials as Topic | 6 | 2014 | 467 | 0.360 |
Why?
|
| HEK293 Cells | 6 | 2018 | 229 | 0.360 |
Why?
|
| HeLa Cells | 9 | 2015 | 265 | 0.360 |
Why?
|
| Phosphorylation | 6 | 2025 | 528 | 0.350 |
Why?
|
| Fatigue | 1 | 2011 | 125 | 0.350 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2011 | 111 | 0.350 |
Why?
|
| S Phase | 1 | 2010 | 19 | 0.350 |
Why?
|
| Gene Expression Regulation, Neoplastic | 4 | 2017 | 857 | 0.350 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2025 | 528 | 0.350 |
Why?
|
| Androgen Antagonists | 1 | 2010 | 11 | 0.340 |
Why?
|
| Ventricular Function, Left | 1 | 2011 | 172 | 0.340 |
Why?
|
| Carrier Proteins | 10 | 2005 | 313 | 0.340 |
Why?
|
| Female | 27 | 2025 | 28171 | 0.340 |
Why?
|
| Ubiquitin-Protein Ligases | 5 | 2010 | 96 | 0.340 |
Why?
|
| Antigens, Surface | 9 | 1990 | 47 | 0.340 |
Why?
|
| Coronary Artery Disease | 3 | 2010 | 294 | 0.340 |
Why?
|
| Embryonic Development | 1 | 2010 | 18 | 0.340 |
Why?
|
| DNA Damage | 2 | 2011 | 305 | 0.330 |
Why?
|
| Neovascularization, Physiologic | 4 | 2011 | 72 | 0.330 |
Why?
|
| Lymphocyte Activation | 9 | 1994 | 172 | 0.330 |
Why?
|
| Metabolic Diseases | 1 | 2010 | 46 | 0.330 |
Why?
|
| Saccharomyces cerevisiae | 6 | 1998 | 176 | 0.330 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2010 | 137 | 0.320 |
Why?
|
| Antibodies, Monoclonal | 12 | 2013 | 481 | 0.320 |
Why?
|
| DNA-Directed DNA Polymerase | 1 | 2010 | 89 | 0.320 |
Why?
|
| Caspases | 3 | 1998 | 104 | 0.320 |
Why?
|
| Cloning, Molecular | 9 | 2000 | 190 | 0.320 |
Why?
|
| Glycolipids | 4 | 1992 | 8 | 0.310 |
Why?
|
| DNA | 2 | 2011 | 549 | 0.310 |
Why?
|
| Adult Stem Cells | 1 | 2009 | 10 | 0.310 |
Why?
|
| Cell Line, Tumor | 8 | 2016 | 1470 | 0.310 |
Why?
|
| Blotting, Western | 8 | 2010 | 590 | 0.300 |
Why?
|
| Caenorhabditis elegans | 2 | 2008 | 139 | 0.300 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2009 | 181 | 0.300 |
Why?
|
| Hemoglobinuria, Paroxysmal | 5 | 1994 | 9 | 0.300 |
Why?
|
| Melanoma | 1 | 2011 | 288 | 0.290 |
Why?
|
| Abdominal Fat | 1 | 2008 | 10 | 0.290 |
Why?
|
| Models, Biological | 6 | 2009 | 735 | 0.290 |
Why?
|
| GTPase-Activating Proteins | 2 | 1997 | 25 | 0.290 |
Why?
|
| RNA, Messenger | 8 | 2014 | 1132 | 0.280 |
Why?
|
| Synaptic Transmission | 1 | 2008 | 66 | 0.280 |
Why?
|
| Caenorhabditis elegans Proteins | 1 | 2008 | 58 | 0.280 |
Why?
|
| Obesity | 2 | 2007 | 1162 | 0.280 |
Why?
|
| Stem Cell Transplantation | 2 | 2006 | 185 | 0.280 |
Why?
|
| Ion Channels | 1 | 2008 | 70 | 0.280 |
Why?
|
| Radiotherapy | 2 | 2008 | 127 | 0.280 |
Why?
|
| Stroke Volume | 4 | 2014 | 155 | 0.280 |
Why?
|
| Integrin alpha4beta1 | 1 | 2007 | 2 | 0.270 |
Why?
|
| Fungal Proteins | 3 | 2000 | 117 | 0.270 |
Why?
|
| Cell Cycle | 2 | 2000 | 230 | 0.270 |
Why?
|
| Histone Deacetylases | 2 | 2005 | 51 | 0.270 |
Why?
|
| Adaptor Proteins, Signal Transducing | 7 | 2006 | 202 | 0.270 |
Why?
|
| Immunoprecipitation | 3 | 2017 | 57 | 0.270 |
Why?
|
| Endocrine Glands | 1 | 2007 | 5 | 0.270 |
Why?
|
| Peptide Hormones | 1 | 2007 | 4 | 0.270 |
Why?
|
| Antibodies, Neoplasm | 2 | 2008 | 28 | 0.270 |
Why?
|
| Cardiomyopathies | 3 | 2014 | 121 | 0.270 |
Why?
|
| Indoles | 2 | 2008 | 278 | 0.260 |
Why?
|
| Transcription Factor RelA | 1 | 2006 | 32 | 0.260 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 8 | 2010 | 582 | 0.260 |
Why?
|
| Sirtuins | 1 | 2006 | 11 | 0.260 |
Why?
|
| Immunohistochemistry | 6 | 2017 | 979 | 0.260 |
Why?
|
| Stroke | 1 | 2012 | 512 | 0.260 |
Why?
|
| Calcium | 3 | 2021 | 376 | 0.260 |
Why?
|
| Yeasts | 2 | 2008 | 9 | 0.250 |
Why?
|
| Repressor Proteins | 4 | 2010 | 155 | 0.250 |
Why?
|
| Corticotropin-Releasing Hormone | 2 | 2023 | 14 | 0.250 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 3 | 2007 | 603 | 0.250 |
Why?
|
| Ubiquitin-Activating Enzymes | 3 | 2021 | 4 | 0.250 |
Why?
|
| Anticholesteremic Agents | 1 | 2005 | 31 | 0.250 |
Why?
|
| Hypercholesterolemia | 1 | 2005 | 38 | 0.240 |
Why?
|
| Apolipoproteins E | 3 | 2005 | 55 | 0.240 |
Why?
|
| Tumor Cells, Cultured | 8 | 2001 | 460 | 0.240 |
Why?
|
| Mice, Inbred C3H | 5 | 2011 | 83 | 0.240 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2018 | 221 | 0.240 |
Why?
|
| Transfection | 9 | 2014 | 357 | 0.240 |
Why?
|
| Topoisomerase II Inhibitors | 1 | 2025 | 6 | 0.240 |
Why?
|
| Coronary Vessels | 3 | 2003 | 166 | 0.240 |
Why?
|
| Hormones, Ectopic | 1 | 2004 | 2 | 0.230 |
Why?
|
| PPAR gamma | 1 | 2005 | 72 | 0.230 |
Why?
|
| Adipose Tissue | 1 | 2007 | 204 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2005 | 75 | 0.230 |
Why?
|
| Immunologic Factors | 1 | 2006 | 117 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 3 | 1 | 2004 | 49 | 0.230 |
Why?
|
| Mitogen-Activated Protein Kinase 1 | 1 | 2004 | 50 | 0.230 |
Why?
|
| Acute Lung Injury | 1 | 2025 | 28 | 0.230 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2011 | 130 | 0.230 |
Why?
|
| Synapses | 1 | 2025 | 74 | 0.230 |
Why?
|
| Receptors, Cytoplasmic and Nuclear | 3 | 2004 | 67 | 0.230 |
Why?
|
| Neonatal Screening | 1 | 2025 | 49 | 0.230 |
Why?
|
| Microtubules | 3 | 2000 | 39 | 0.230 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 3 | 2018 | 134 | 0.230 |
Why?
|
| Cell Proliferation | 4 | 2010 | 1023 | 0.220 |
Why?
|
| Myocytes, Smooth Muscle | 1 | 2004 | 93 | 0.220 |
Why?
|
| Interleukin-6 | 4 | 2016 | 278 | 0.220 |
Why?
|
| Antigens, CD | 4 | 2004 | 218 | 0.220 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2004 | 151 | 0.220 |
Why?
|
| Chromosomes | 2 | 1999 | 30 | 0.220 |
Why?
|
| DNA, Complementary | 8 | 2006 | 135 | 0.220 |
Why?
|
| Microglia | 1 | 2025 | 113 | 0.220 |
Why?
|
| Cell Adhesion Molecules | 3 | 2013 | 86 | 0.210 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2023 | 10 | 0.210 |
Why?
|
| Hearing Loss | 1 | 2025 | 96 | 0.200 |
Why?
|
| Cell Transdifferentiation | 1 | 2022 | 8 | 0.200 |
Why?
|
| Embryo, Mammalian | 4 | 2013 | 67 | 0.200 |
Why?
|
| Homeostasis | 3 | 2021 | 201 | 0.200 |
Why?
|
| Down-Regulation | 4 | 2013 | 346 | 0.200 |
Why?
|
| Cardiotonic Agents | 2 | 2016 | 82 | 0.190 |
Why?
|
| Osteoporosis | 1 | 2004 | 162 | 0.190 |
Why?
|
| Cytochrome c Group | 2 | 1998 | 4 | 0.190 |
Why?
|
| Sympathetic Nervous System | 1 | 2022 | 18 | 0.190 |
Why?
|
| Medulla Oblongata | 1 | 2022 | 20 | 0.190 |
Why?
|
| Centromere | 2 | 2016 | 13 | 0.190 |
Why?
|
| Potassium | 1 | 2022 | 58 | 0.190 |
Why?
|
| Phospholipase C beta | 1 | 2021 | 2 | 0.190 |
Why?
|
| Electron Transport | 2 | 1998 | 26 | 0.190 |
Why?
|
| Second Messenger Systems | 1 | 2021 | 13 | 0.190 |
Why?
|
| Electrocardiography | 2 | 2014 | 268 | 0.190 |
Why?
|
| Carbon-Nitrogen Lyases | 2 | 2005 | 2 | 0.190 |
Why?
|
| Arterial Pressure | 1 | 2022 | 45 | 0.190 |
Why?
|
| Chemokines | 1 | 2021 | 79 | 0.180 |
Why?
|
| Neurogenesis | 1 | 2021 | 27 | 0.180 |
Why?
|
| Neovascularization, Pathologic | 3 | 2011 | 153 | 0.180 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2016 | 108 | 0.180 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 316 | 0.180 |
Why?
|
| Graft Occlusion, Vascular | 1 | 2002 | 75 | 0.180 |
Why?
|
| Recombinant Proteins | 6 | 2006 | 483 | 0.180 |
Why?
|
| Replication Protein A | 2 | 2011 | 6 | 0.180 |
Why?
|
| Heterotrimeric GTP-Binding Proteins | 1 | 2000 | 7 | 0.180 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2023 | 203 | 0.180 |
Why?
|
| Dyneins | 3 | 2000 | 5 | 0.180 |
Why?
|
| Sense Organs | 1 | 2000 | 2 | 0.180 |
Why?
|
| DiGeorge Syndrome | 1 | 2000 | 19 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 22 | 1 | 2000 | 39 | 0.170 |
Why?
|
| Recombinant Fusion Proteins | 7 | 2015 | 177 | 0.170 |
Why?
|
| Incidence | 2 | 2017 | 1062 | 0.170 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 1990 | 54 | 0.170 |
Why?
|
| Drosophila | 1 | 2000 | 17 | 0.170 |
Why?
|
| Drosophila Proteins | 1 | 2000 | 25 | 0.170 |
Why?
|
| Glucocorticoids | 1 | 2022 | 235 | 0.170 |
Why?
|
| Adaptive Immunity | 1 | 2020 | 34 | 0.170 |
Why?
|
| Recombination, Genetic | 2 | 2011 | 109 | 0.170 |
Why?
|
| Proteasome Endopeptidase Complex | 4 | 2007 | 117 | 0.170 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 1997 | 39 | 0.170 |
Why?
|
| Chromosome Deletion | 1 | 2000 | 142 | 0.160 |
Why?
|
| Hybridomas | 4 | 1992 | 11 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2013 | 183 | 0.160 |
Why?
|
| Alzheimer Disease | 1 | 2004 | 332 | 0.160 |
Why?
|
| Chromosome Mapping | 5 | 2000 | 154 | 0.160 |
Why?
|
| Rats | 7 | 2023 | 3220 | 0.160 |
Why?
|
| Thiazolidinediones | 1 | 2000 | 83 | 0.160 |
Why?
|
| Oxidative Stress | 4 | 2010 | 807 | 0.160 |
Why?
|
| Models, Genetic | 3 | 2011 | 169 | 0.160 |
Why?
|
| Immunoblotting | 2 | 2017 | 116 | 0.160 |
Why?
|
| Anti-Inflammatory Agents | 2 | 2012 | 166 | 0.150 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 1998 | 13 | 0.150 |
Why?
|
| Cell Membrane Permeability | 1 | 1998 | 25 | 0.150 |
Why?
|
| Protein Transport | 2 | 2010 | 180 | 0.150 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 133 | 0.150 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 6 | 1 | 2018 | 2 | 0.150 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2018 | 11 | 0.150 |
Why?
|
| Methylation | 2 | 2016 | 126 | 0.150 |
Why?
|
| Trans-Activators | 2 | 2012 | 135 | 0.150 |
Why?
|
| MAP Kinase Kinase 7 | 1 | 2018 | 5 | 0.150 |
Why?
|
| Receptors, Lymphocyte Homing | 1 | 1998 | 1 | 0.150 |
Why?
|
| Integrins | 1 | 1998 | 31 | 0.140 |
Why?
|
| Substrate Specificity | 3 | 2006 | 193 | 0.140 |
Why?
|
| Forecasting | 2 | 2016 | 154 | 0.140 |
Why?
|
| Chondrocytes | 1 | 2018 | 41 | 0.140 |
Why?
|
| Macrophages, Peritoneal | 1 | 1998 | 32 | 0.140 |
Why?
|
| Cytoplasm | 5 | 2009 | 94 | 0.140 |
Why?
|
| Cell Fusion | 3 | 2007 | 11 | 0.140 |
Why?
|
| Amino Acid Substitution | 3 | 2015 | 82 | 0.140 |
Why?
|
| Acute Coronary Syndrome | 2 | 2009 | 80 | 0.140 |
Why?
|
| Bone Development | 1 | 2018 | 66 | 0.140 |
Why?
|
| Gene Library | 5 | 2003 | 44 | 0.140 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 138 | 0.140 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1997 | 12 | 0.140 |
Why?
|
| Transcriptional Activation | 2 | 2009 | 122 | 0.140 |
Why?
|
| Enzyme Activation | 4 | 2015 | 270 | 0.130 |
Why?
|
| Protein Stability | 1 | 2017 | 45 | 0.130 |
Why?
|
| Morbidity | 1 | 2017 | 145 | 0.130 |
Why?
|
| Telomere Shortening | 1 | 2016 | 1 | 0.130 |
Why?
|
| Fluorouracil | 2 | 2025 | 59 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase 7 | 2 | 2015 | 5 | 0.130 |
Why?
|
| Bone Marrow Transplantation | 2 | 2014 | 113 | 0.130 |
Why?
|
| Resistin | 2 | 2008 | 6 | 0.130 |
Why?
|
| Antimetabolites, Antineoplastic | 2 | 2008 | 39 | 0.130 |
Why?
|
| Ethanolamines | 2 | 1994 | 13 | 0.130 |
Why?
|
| Cadherins | 2 | 2008 | 62 | 0.130 |
Why?
|
| Interleukin-1 | 4 | 2003 | 107 | 0.130 |
Why?
|
| G2 Phase | 1 | 2016 | 13 | 0.130 |
Why?
|
| In Situ Hybridization | 3 | 2007 | 64 | 0.130 |
Why?
|
| Umbilical Veins | 3 | 2010 | 21 | 0.130 |
Why?
|
| Sequence Alignment | 4 | 2000 | 125 | 0.130 |
Why?
|
| Flow Cytometry | 5 | 2003 | 478 | 0.130 |
Why?
|
| Radiation Injuries | 2 | 2010 | 110 | 0.130 |
Why?
|
| Withholding Treatment | 1 | 2016 | 19 | 0.130 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2016 | 25 | 0.130 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 85 | 0.130 |
Why?
|
| Isocitrates | 1 | 2015 | 1 | 0.120 |
Why?
|
| Cullin Proteins | 3 | 2000 | 5 | 0.120 |
Why?
|
| Enzyme Inhibitors | 5 | 2008 | 372 | 0.120 |
Why?
|
| Islets of Langerhans | 1 | 2015 | 26 | 0.120 |
Why?
|
| NF-kappa B | 2 | 2011 | 322 | 0.120 |
Why?
|
| Cholesterol, LDL | 2 | 2005 | 43 | 0.120 |
Why?
|
| Combined Modality Therapy | 1 | 2017 | 639 | 0.120 |
Why?
|
| Troponin T | 2 | 2006 | 12 | 0.120 |
Why?
|
| Pyridines | 2 | 2008 | 132 | 0.120 |
Why?
|
| Protein Isoforms | 2 | 2010 | 123 | 0.120 |
Why?
|
| Insulin Resistance | 2 | 2008 | 275 | 0.120 |
Why?
|
| Ribosomal Protein S6 Kinases, 90-kDa | 1 | 2015 | 7 | 0.120 |
Why?
|
| Aspirin | 2 | 2009 | 115 | 0.120 |
Why?
|
| Aged | 5 | 2016 | 10121 | 0.120 |
Why?
|
| Membrane Proteins | 3 | 1992 | 335 | 0.120 |
Why?
|
| Mutation, Missense | 1 | 2015 | 108 | 0.120 |
Why?
|
| Osteoblasts | 1 | 2018 | 475 | 0.110 |
Why?
|
| Potassium Channel Blockers | 1 | 2014 | 16 | 0.110 |
Why?
|
| Middle Aged | 6 | 2016 | 13028 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2010 | 1378 | 0.110 |
Why?
|
| Electric Stimulation | 1 | 2014 | 107 | 0.110 |
Why?
|
| Mice, Nude | 5 | 2014 | 265 | 0.110 |
Why?
|
| Glutathione Transferase | 3 | 2005 | 174 | 0.110 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2015 | 99 | 0.110 |
Why?
|
| Acoustic Stimulation | 1 | 2014 | 93 | 0.110 |
Why?
|
| Feasibility Studies | 1 | 2016 | 406 | 0.110 |
Why?
|
| Action Potentials | 1 | 2014 | 120 | 0.110 |
Why?
|
| Caspase 3 | 3 | 1998 | 95 | 0.110 |
Why?
|
| Myostatin | 1 | 2013 | 10 | 0.110 |
Why?
|
| HLA Antigens | 2 | 2004 | 56 | 0.110 |
Why?
|
| Sequence Deletion | 2 | 2012 | 73 | 0.110 |
Why?
|
| Fibrosis | 2 | 2011 | 196 | 0.110 |
Why?
|
| Muscle Development | 1 | 2013 | 24 | 0.110 |
Why?
|
| Forkhead Transcription Factors | 1 | 2014 | 116 | 0.110 |
Why?
|
| Meiosis | 3 | 1994 | 74 | 0.110 |
Why?
|
| Cell Membrane | 4 | 2015 | 245 | 0.110 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2011 | 1546 | 0.110 |
Why?
|
| RNA Interference | 3 | 2015 | 181 | 0.110 |
Why?
|
| Antigens, Ly | 3 | 1990 | 12 | 0.110 |
Why?
|
| Graft Survival | 2 | 2004 | 160 | 0.110 |
Why?
|
| Chemokine CCL2 | 2 | 2005 | 69 | 0.100 |
Why?
|
| Animals, Newborn | 1 | 2014 | 362 | 0.100 |
Why?
|
| Risk Assessment | 2 | 2010 | 1327 | 0.100 |
Why?
|
| Myocarditis | 1 | 1994 | 49 | 0.100 |
Why?
|
| Cell Division | 4 | 2004 | 291 | 0.100 |
Why?
|
| Analysis of Variance | 1 | 2014 | 554 | 0.100 |
Why?
|
| Hemorheology | 1 | 2013 | 11 | 0.100 |
Why?
|
| Autoimmune Diseases | 1 | 1994 | 86 | 0.100 |
Why?
|
| Insulin | 1 | 2015 | 479 | 0.100 |
Why?
|
| Prognosis | 3 | 2014 | 2099 | 0.100 |
Why?
|
| Head and Neck Neoplasms | 1 | 2016 | 288 | 0.100 |
Why?
|
| Rats, Inbred WKY | 2 | 2023 | 34 | 0.100 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2022 | 151 | 0.100 |
Why?
|
| Gene Expression Profiling | 2 | 2012 | 1105 | 0.100 |
Why?
|
| Hippocampus | 1 | 2014 | 201 | 0.100 |
Why?
|
| Electroencephalography | 1 | 2014 | 312 | 0.100 |
Why?
|
| Sensitivity and Specificity | 2 | 2005 | 891 | 0.100 |
Why?
|
| Interleukin-10 | 1 | 2012 | 84 | 0.100 |
Why?
|
| Rheumatic Diseases | 1 | 1992 | 16 | 0.100 |
Why?
|
| Ubiquitin-Protein Ligase Complexes | 1 | 2012 | 3 | 0.100 |
Why?
|
| Luminescent Measurements | 1 | 2011 | 16 | 0.100 |
Why?
|
| Myeloid Cells | 1 | 2012 | 39 | 0.090 |
Why?
|
| Time | 1 | 2011 | 28 | 0.090 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 3392 | 0.090 |
Why?
|
| Ubiquitin-Conjugating Enzymes | 3 | 2005 | 6 | 0.090 |
Why?
|
| Tissue Distribution | 3 | 2008 | 171 | 0.090 |
Why?
|
| Genes, Reporter | 1 | 2011 | 88 | 0.090 |
Why?
|
| Taiwan | 1 | 2011 | 28 | 0.090 |
Why?
|
| GTP-Binding Proteins | 2 | 1991 | 85 | 0.090 |
Why?
|
| Endostatins | 1 | 2011 | 4 | 0.090 |
Why?
|
| Cytosine Deaminase | 1 | 2011 | 8 | 0.090 |
Why?
|
| Pentosyltransferases | 1 | 2011 | 4 | 0.090 |
Why?
|
| Cell Polarity | 2 | 2005 | 16 | 0.090 |
Why?
|
| International Classification of Diseases | 1 | 2011 | 67 | 0.090 |
Why?
|
| Cell Hypoxia | 2 | 2010 | 83 | 0.090 |
Why?
|
| Rad51 Recombinase | 1 | 2011 | 25 | 0.090 |
Why?
|
| Analgesics | 1 | 1992 | 107 | 0.090 |
Why?
|
| Membrane Glycoproteins | 2 | 1994 | 244 | 0.090 |
Why?
|
| Stomach Neoplasms | 1 | 2014 | 194 | 0.090 |
Why?
|
| Vascular Endothelial Growth Factors | 1 | 2010 | 14 | 0.090 |
Why?
|
| Protein Inhibitors of Activated STAT | 1 | 2010 | 2 | 0.090 |
Why?
|
| Expressed Sequence Tags | 2 | 2000 | 8 | 0.090 |
Why?
|
| Congresses as Topic | 1 | 2011 | 48 | 0.090 |
Why?
|
| Interdisciplinary Communication | 1 | 2011 | 57 | 0.090 |
Why?
|
| Promoter Regions, Genetic | 3 | 2010 | 467 | 0.090 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2002 | 21 | 0.090 |
Why?
|
| Drug Therapy, Combination | 2 | 2009 | 395 | 0.090 |
Why?
|
| Cell Nucleus | 3 | 2009 | 187 | 0.090 |
Why?
|
| Polycomb-Group Proteins | 1 | 2010 | 8 | 0.080 |
Why?
|
| Mice, Inbred BALB C | 5 | 2014 | 312 | 0.080 |
Why?
|
| Plasmids | 3 | 2005 | 163 | 0.080 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2010 | 54 | 0.080 |
Why?
|
| Two-Hybrid System Techniques | 4 | 2004 | 23 | 0.080 |
Why?
|
| Culture Media, Serum-Free | 2 | 2000 | 15 | 0.080 |
Why?
|
| Adult | 4 | 2016 | 14161 | 0.080 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 2 | 2007 | 8 | 0.080 |
Why?
|
| Protein Structure, Tertiary | 3 | 2005 | 242 | 0.080 |
Why?
|
| Luminescent Proteins | 2 | 2022 | 54 | 0.080 |
Why?
|
| E-Selectin | 3 | 2013 | 13 | 0.080 |
Why?
|
| Pain | 1 | 1992 | 362 | 0.080 |
Why?
|
| Molecular Chaperones | 3 | 2005 | 66 | 0.080 |
Why?
|
| E1A-Associated p300 Protein | 1 | 2009 | 9 | 0.080 |
Why?
|
| Ubiquitination | 2 | 2025 | 47 | 0.080 |
Why?
|
| DNA Replication | 1 | 2010 | 160 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2015 | 560 | 0.080 |
Why?
|
| Cooperative Behavior | 1 | 2011 | 227 | 0.080 |
Why?
|
| Membrane Potentials | 2 | 2022 | 109 | 0.080 |
Why?
|
| Benzenesulfonates | 1 | 2008 | 10 | 0.080 |
Why?
|
| Patient Care Team | 1 | 2011 | 272 | 0.080 |
Why?
|
| Niacinamide | 1 | 2008 | 23 | 0.080 |
Why?
|
| Phenylurea Compounds | 1 | 2008 | 17 | 0.080 |
Why?
|
| Leukemia, Myeloid | 2 | 1998 | 42 | 0.080 |
Why?
|
| Anaphase | 2 | 2000 | 2 | 0.080 |
Why?
|
| DNA Fragmentation | 2 | 1998 | 55 | 0.080 |
Why?
|
| RNA, Small Interfering | 2 | 2010 | 213 | 0.070 |
Why?
|
| Ticlopidine | 1 | 2009 | 56 | 0.070 |
Why?
|
| Disease Progression | 3 | 2012 | 871 | 0.070 |
Why?
|
| Pyrroles | 1 | 2008 | 71 | 0.070 |
Why?
|
| Cholinergic Fibers | 1 | 2008 | 8 | 0.070 |
Why?
|
| Cations | 1 | 2008 | 9 | 0.070 |
Why?
|
| Texas | 1 | 2008 | 143 | 0.070 |
Why?
|
| Neuromuscular Junction | 1 | 2008 | 9 | 0.070 |
Why?
|
| DNA Primers | 4 | 2005 | 208 | 0.070 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 78 | 0.070 |
Why?
|
| Young Adult | 2 | 2016 | 4329 | 0.070 |
Why?
|
| Torsades de Pointes | 1 | 2008 | 15 | 0.070 |
Why?
|
| Prevalence | 1 | 2011 | 1006 | 0.070 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 2 | 2000 | 129 | 0.070 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 301 | 0.070 |
Why?
|
| Animals, Genetically Modified | 1 | 2008 | 52 | 0.070 |
Why?
|
| Bradycardia | 1 | 2008 | 38 | 0.070 |
Why?
|
| Protease Inhibitors | 2 | 1998 | 61 | 0.070 |
Why?
|
| Erythroid Precursor Cells | 1 | 2007 | 15 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2007 | 18 | 0.070 |
Why?
|
| Molecular Weight | 4 | 1999 | 82 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 199 | 0.070 |
Why?
|
| Adiponectin | 1 | 2008 | 46 | 0.070 |
Why?
|
| Thermodynamics | 1 | 2007 | 35 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2008 | 62 | 0.070 |
Why?
|
| Species Specificity | 2 | 2004 | 192 | 0.070 |
Why?
|
| Thrombolytic Therapy | 1 | 2008 | 110 | 0.070 |
Why?
|
| Survival Rate | 1 | 2010 | 945 | 0.070 |
Why?
|
| Necrosis | 2 | 1998 | 176 | 0.070 |
Why?
|
| Erythropoietin | 1 | 2007 | 50 | 0.070 |
Why?
|
| Antihypertensive Agents | 1 | 2008 | 132 | 0.070 |
Why?
|
| Androgens | 1 | 2007 | 70 | 0.070 |
Why?
|
| In Situ Hybridization, Fluorescence | 2 | 2005 | 263 | 0.070 |
Why?
|
| Anemia | 1 | 2007 | 74 | 0.070 |
Why?
|
| Serotonin | 1 | 2008 | 146 | 0.070 |
Why?
|
| Venous Thrombosis | 1 | 2008 | 90 | 0.070 |
Why?
|
| Myocardial Ischemia | 1 | 2008 | 121 | 0.070 |
Why?
|
| Cyclin D | 1 | 2006 | 18 | 0.070 |
Why?
|
| Cell Survival | 2 | 2011 | 612 | 0.070 |
Why?
|
| Cyclins | 1 | 2006 | 38 | 0.070 |
Why?
|
| Coculture Techniques | 1 | 2007 | 144 | 0.070 |
Why?
|
| Neutrophils | 2 | 2005 | 147 | 0.070 |
Why?
|
| Ubiquitin Thiolesterase | 3 | 2004 | 19 | 0.070 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 236 | 0.070 |
Why?
|
| Cisplatin | 1 | 2008 | 285 | 0.070 |
Why?
|
| Leptin | 1 | 2008 | 148 | 0.070 |
Why?
|
| Sirtuin 1 | 1 | 2006 | 29 | 0.070 |
Why?
|
| Fetus | 1 | 2007 | 194 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2008 | 227 | 0.060 |
Why?
|
| Thalidomide | 1 | 2008 | 377 | 0.060 |
Why?
|
| Thymus Gland | 1 | 1986 | 41 | 0.060 |
Why?
|
| Bone Neoplasms | 1 | 2008 | 184 | 0.060 |
Why?
|
| P-Selectin | 3 | 2009 | 30 | 0.060 |
Why?
|
| Binding Sites | 4 | 2003 | 377 | 0.060 |
Why?
|
| Transplantation, Heterologous | 2 | 2004 | 79 | 0.060 |
Why?
|
| Ultrasonography | 1 | 2008 | 430 | 0.060 |
Why?
|
| Adolescent | 2 | 2016 | 6739 | 0.060 |
Why?
|
| Genes, Fungal | 1 | 1986 | 31 | 0.060 |
Why?
|
| Platelet Adhesiveness | 1 | 2005 | 13 | 0.060 |
Why?
|
| Comorbidity | 1 | 2008 | 625 | 0.060 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2006 | 30 | 0.060 |
Why?
|
| Proline | 1 | 2005 | 31 | 0.060 |
Why?
|
| Peroxynitrous Acid | 1 | 2005 | 33 | 0.060 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 2006 | 44 | 0.060 |
Why?
|
| Muscle, Smooth | 1 | 2005 | 64 | 0.060 |
Why?
|
| Prostaglandin D2 | 1 | 2005 | 22 | 0.060 |
Why?
|
| Complement System Proteins | 1 | 2005 | 32 | 0.060 |
Why?
|
| Endocarditis | 1 | 2006 | 31 | 0.060 |
Why?
|
| Endocarditis, Bacterial | 1 | 2006 | 43 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 15 | 1 | 2005 | 9 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 12 | 1 | 2005 | 14 | 0.060 |
Why?
|
| Blood Pressure | 1 | 2008 | 537 | 0.060 |
Why?
|
| Interleukin-8 | 1 | 2005 | 86 | 0.060 |
Why?
|
| Mannose | 3 | 1994 | 16 | 0.060 |
Why?
|
| Practice Guidelines as Topic | 1 | 2008 | 488 | 0.060 |
Why?
|
| Risk Reduction Behavior | 1 | 2005 | 58 | 0.060 |
Why?
|
| Teratoma | 1 | 2005 | 24 | 0.060 |
Why?
|
| Hybrid Cells | 1 | 2004 | 6 | 0.060 |
Why?
|
| Long-Term Potentiation | 1 | 2025 | 17 | 0.060 |
Why?
|
| Interphase | 1 | 2004 | 10 | 0.060 |
Why?
|
| X Chromosome | 1 | 2004 | 13 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2014 | 5422 | 0.060 |
Why?
|
| Ontario | 1 | 2025 | 55 | 0.060 |
Why?
|
| Chromones | 1 | 2004 | 17 | 0.060 |
Why?
|
| Hearing Tests | 1 | 2025 | 27 | 0.060 |
Why?
|
| Chromosomes, Human | 1 | 2004 | 41 | 0.060 |
Why?
|
| Neuronal Plasticity | 1 | 2025 | 45 | 0.060 |
Why?
|
| Nitriles | 1 | 2004 | 53 | 0.060 |
Why?
|
| Razoxane | 1 | 2004 | 1 | 0.060 |
Why?
|
| Up-Regulation | 1 | 2006 | 454 | 0.060 |
Why?
|
| Histone Deacetylase 1 | 1 | 2004 | 8 | 0.060 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 1984 | 36 | 0.060 |
Why?
|
| Models, Immunological | 1 | 2004 | 8 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2010 | 1165 | 0.060 |
Why?
|
| Coronary Disease | 1 | 2005 | 152 | 0.060 |
Why?
|
| Chromatography, Thin Layer | 3 | 1992 | 25 | 0.060 |
Why?
|
| Morpholines | 1 | 2004 | 66 | 0.060 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2004 | 94 | 0.060 |
Why?
|
| Models, Cardiovascular | 1 | 2004 | 20 | 0.060 |
Why?
|
| Homeodomain Proteins | 1 | 2004 | 80 | 0.060 |
Why?
|
| Butadienes | 1 | 2004 | 49 | 0.060 |
Why?
|
| Hydrolysis | 2 | 2001 | 69 | 0.060 |
Why?
|
| Pericardium | 1 | 2004 | 29 | 0.060 |
Why?
|
| Protein Precursors | 1 | 2004 | 42 | 0.060 |
Why?
|
| Antineoplastic Agents, Alkylating | 1 | 2004 | 77 | 0.050 |
Why?
|
| Genetic Testing | 1 | 2025 | 129 | 0.050 |
Why?
|
| Angioplasty, Balloon, Coronary | 1 | 2005 | 136 | 0.050 |
Why?
|
| Osteogenesis | 1 | 2007 | 366 | 0.050 |
Why?
|
| Nuclear Localization Signals | 2 | 2006 | 6 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2004 | 169 | 0.050 |
Why?
|
| Antigens, Differentiation | 1 | 2003 | 16 | 0.050 |
Why?
|
| Imidazoles | 1 | 2004 | 124 | 0.050 |
Why?
|
| Diabetes Complications | 1 | 2004 | 122 | 0.050 |
Why?
|
| Herpesvirus 8, Human | 1 | 2005 | 98 | 0.050 |
Why?
|
| Microscopy, Confocal | 2 | 2000 | 86 | 0.050 |
Why?
|
| Aorta | 1 | 2004 | 165 | 0.050 |
Why?
|
| Mutagenesis, Site-Directed | 4 | 2006 | 95 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2005 | 265 | 0.050 |
Why?
|
| Cell Nucleus Structures | 1 | 2003 | 1 | 0.050 |
Why?
|
| Adrenal Cortex | 1 | 2022 | 2 | 0.050 |
Why?
|
| Eukaryotic Cells | 1 | 2003 | 15 | 0.050 |
Why?
|
| Estrogen Replacement Therapy | 1 | 2003 | 28 | 0.050 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 2022 | 30 | 0.050 |
Why?
|
| Heat-Shock Response | 1 | 2003 | 28 | 0.050 |
Why?
|
| N-Methylaspartate | 1 | 2022 | 18 | 0.050 |
Why?
|
| Receptors, Corticotropin-Releasing Hormone | 1 | 2022 | 8 | 0.050 |
Why?
|
| Mammals | 2 | 1992 | 61 | 0.050 |
Why?
|
| Heat-Shock Proteins | 1 | 2003 | 103 | 0.050 |
Why?
|
| Neuroanatomical Tract-Tracing Techniques | 1 | 2022 | 2 | 0.050 |
Why?
|
| Leupeptins | 1 | 2002 | 5 | 0.050 |
Why?
|
| Vesicular Glutamate Transport Protein 2 | 1 | 2022 | 6 | 0.050 |
Why?
|
| beta Catenin | 1 | 2022 | 102 | 0.050 |
Why?
|
| Biopsy | 1 | 2004 | 605 | 0.050 |
Why?
|
| Wnt Signaling Pathway | 1 | 2022 | 94 | 0.050 |
Why?
|
| Rats, Inbred SHR | 1 | 2022 | 42 | 0.050 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2022 | 116 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 3 | 2003 | 56 | 0.050 |
Why?
|
| Neoplasm Metastasis | 2 | 2013 | 243 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2003 | 122 | 0.050 |
Why?
|
| Receptors, N-Methyl-D-Aspartate | 1 | 2022 | 79 | 0.050 |
Why?
|
| Mice, Mutant Strains | 1 | 2021 | 70 | 0.050 |
Why?
|
| Amino Acid Motifs | 1 | 2021 | 57 | 0.050 |
Why?
|
| Liver | 1 | 2007 | 1156 | 0.050 |
Why?
|
| Polysaccharides | 2 | 1992 | 57 | 0.050 |
Why?
|
| Predictive Value of Tests | 1 | 2004 | 944 | 0.050 |
Why?
|
| Regional Blood Flow | 3 | 2015 | 109 | 0.050 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2015 | 34 | 0.050 |
Why?
|
| Angioplasty, Balloon | 1 | 2002 | 68 | 0.050 |
Why?
|
| Carotid Stenosis | 1 | 2002 | 66 | 0.050 |
Why?
|
| Breast Neoplasms | 2 | 2010 | 1212 | 0.050 |
Why?
|
| Hypolipidemic Agents | 1 | 2001 | 29 | 0.050 |
Why?
|
| Interferons | 1 | 2001 | 40 | 0.040 |
Why?
|
| Selectins | 1 | 2000 | 1 | 0.040 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 1 | 2000 | 20 | 0.040 |
Why?
|
| Precipitin Tests | 1 | 2000 | 31 | 0.040 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2000 | 16 | 0.040 |
Why?
|
| Bromodeoxyuridine | 1 | 2000 | 19 | 0.040 |
Why?
|
| Physical Chromosome Mapping | 1 | 2000 | 8 | 0.040 |
Why?
|
| Cell Surface Extensions | 1 | 2000 | 3 | 0.040 |
Why?
|
| Age Factors | 1 | 2004 | 1132 | 0.040 |
Why?
|
| Phosphoproteins | 1 | 2001 | 119 | 0.040 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 1026 | 0.040 |
Why?
|
| Propionates | 1 | 2000 | 24 | 0.040 |
Why?
|
| Proliferating Cell Nuclear Antigen | 1 | 2000 | 69 | 0.040 |
Why?
|
| Chromatography, High Pressure Liquid | 2 | 1992 | 339 | 0.040 |
Why?
|
| Etoposide | 1 | 2000 | 74 | 0.040 |
Why?
|
| Coronary Thrombosis | 1 | 2000 | 23 | 0.040 |
Why?
|
| Microfilament Proteins | 1 | 2000 | 43 | 0.040 |
Why?
|
| Antibodies | 2 | 1999 | 159 | 0.040 |
Why?
|
| Microscopy, Electron, Scanning | 1 | 2000 | 45 | 0.040 |
Why?
|
| Mesenteric Arteries | 2 | 1997 | 43 | 0.040 |
Why?
|
| Protein Subunits | 1 | 2000 | 79 | 0.040 |
Why?
|
| Phosphatidylinositol Diacylglycerol-Lyase | 2 | 1992 | 4 | 0.040 |
Why?
|
| Genes, Dominant | 1 | 2000 | 21 | 0.040 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2000 | 65 | 0.040 |
Why?
|
| Exons | 1 | 2000 | 102 | 0.040 |
Why?
|
| Time Factors | 3 | 2018 | 2968 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2016 | 721 | 0.040 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2000 | 4 | 0.040 |
Why?
|
| Cell Lineage | 1 | 2000 | 85 | 0.040 |
Why?
|
| Point Mutation | 1 | 2000 | 67 | 0.040 |
Why?
|
| von Hippel-Lindau Disease | 1 | 1999 | 4 | 0.040 |
Why?
|
| Phosphoric Diester Hydrolases | 2 | 1992 | 48 | 0.040 |
Why?
|
| Melanocytes | 1 | 2000 | 39 | 0.040 |
Why?
|
| Chromans | 1 | 2000 | 35 | 0.040 |
Why?
|
| Thiazoles | 1 | 2000 | 55 | 0.040 |
Why?
|
| Genes, Tumor Suppressor | 1 | 1999 | 74 | 0.040 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 1999 | 19 | 0.040 |
Why?
|
| Monocytes | 1 | 2000 | 130 | 0.040 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 3 | 1990 | 11 | 0.040 |
Why?
|
| Xanthine | 1 | 1998 | 2 | 0.040 |
Why?
|
| Pregnancy | 1 | 2006 | 2680 | 0.040 |
Why?
|
| Thiocarbamates | 1 | 1998 | 5 | 0.040 |
Why?
|
| Cycloheximide | 1 | 1998 | 35 | 0.040 |
Why?
|
| Thiolester Hydrolases | 1 | 1998 | 6 | 0.040 |
Why?
|
| Citric Acid Cycle | 1 | 1998 | 18 | 0.040 |
Why?
|
| Rotenone | 1 | 1998 | 15 | 0.040 |
Why?
|
| Xanthine Oxidase | 1 | 1998 | 14 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2014 | 591 | 0.040 |
Why?
|
| Leukemia, Promyelocytic, Acute | 1 | 1998 | 12 | 0.040 |
Why?
|
| Oxidation-Reduction | 2 | 2010 | 326 | 0.040 |
Why?
|
| Genes, bcl-2 | 1 | 1998 | 9 | 0.040 |
Why?
|
| Cell Movement | 1 | 2000 | 268 | 0.040 |
Why?
|
| Brain | 2 | 2021 | 1323 | 0.040 |
Why?
|
| Colonic Neoplasms | 2 | 2010 | 163 | 0.040 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 1998 | 61 | 0.040 |
Why?
|
| Microscopy, Fluorescence | 2 | 1997 | 160 | 0.040 |
Why?
|
| Stem Cell Niche | 1 | 2018 | 12 | 0.040 |
Why?
|
| Tretinoin | 1 | 1998 | 54 | 0.040 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2018 | 29 | 0.040 |
Why?
|
| Aging, Premature | 1 | 2018 | 5 | 0.040 |
Why?
|
| Integrin alpha4 | 1 | 1998 | 2 | 0.040 |
Why?
|
| Pyrrolidines | 1 | 1998 | 69 | 0.040 |
Why?
|
| Mercaptoethanol | 1 | 1997 | 5 | 0.040 |
Why?
|
| Receptors, Endothelin | 1 | 1997 | 7 | 0.040 |
Why?
|
| Peptide Fragments | 3 | 2009 | 203 | 0.040 |
Why?
|
| X-Ray Microtomography | 1 | 2018 | 79 | 0.040 |
Why?
|
| Epitope Mapping | 1 | 1997 | 7 | 0.040 |
Why?
|
| Cell Death | 1 | 1998 | 177 | 0.040 |
Why?
|
| Genetic Vectors | 2 | 2011 | 128 | 0.030 |
Why?
|
| Staurosporine | 1 | 1997 | 13 | 0.030 |
Why?
|
| Infant, Newborn | 1 | 2025 | 2867 | 0.030 |
Why?
|
| Caspase 1 | 1 | 1997 | 23 | 0.030 |
Why?
|
| Epitopes | 3 | 1986 | 65 | 0.030 |
Why?
|
| Receptors, Tumor Necrosis Factor, Type I | 1 | 1997 | 39 | 0.030 |
Why?
|
| Fas-Associated Death Domain Protein | 1 | 1996 | 6 | 0.030 |
Why?
|
| Carbohydrate Sequence | 2 | 1993 | 10 | 0.030 |
Why?
|
| Rabbits | 1 | 1997 | 375 | 0.030 |
Why?
|
| Spleen | 2 | 1996 | 172 | 0.030 |
Why?
|
| Proteins | 1 | 1999 | 348 | 0.030 |
Why?
|
| Antioxidants | 1 | 1998 | 256 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 1997 | 53 | 0.030 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 2 | 1 | 2016 | 1 | 0.030 |
Why?
|
| Nitrosamines | 1 | 2016 | 9 | 0.030 |
Why?
|
| Protein Conformation | 1 | 1996 | 176 | 0.030 |
Why?
|
| Infant | 1 | 2025 | 3733 | 0.030 |
Why?
|
| Tissue Plasminogen Activator | 1 | 1997 | 109 | 0.030 |
Why?
|
| Laryngeal Neoplasms | 1 | 2016 | 45 | 0.030 |
Why?
|
| Glycosylation | 2 | 1994 | 106 | 0.030 |
Why?
|
| Fibrinolytic Agents | 1 | 1997 | 128 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 1997 | 253 | 0.030 |
Why?
|
| NADP | 1 | 2015 | 22 | 0.030 |
Why?
|
| Exocytosis | 1 | 2015 | 12 | 0.030 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 1996 | 29 | 0.030 |
Why?
|
| Microscopy, Interference | 1 | 1995 | 1 | 0.030 |
Why?
|
| Secretory Vesicles | 1 | 2015 | 11 | 0.030 |
Why?
|
| Microscopy, Video | 1 | 1995 | 13 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2015 | 46 | 0.030 |
Why?
|
| Cell Compartmentation | 1 | 1995 | 10 | 0.030 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2015 | 20 | 0.030 |
Why?
|
| Periodicity | 1 | 1995 | 26 | 0.030 |
Why?
|
| Catalytic Domain | 1 | 2015 | 60 | 0.030 |
Why?
|
| Organ Specificity | 1 | 2015 | 115 | 0.030 |
Why?
|
| Image Enhancement | 1 | 1995 | 52 | 0.030 |
Why?
|
| Blotting, Northern | 2 | 2008 | 106 | 0.030 |
Why?
|
| Retrospective Studies | 3 | 2014 | 6607 | 0.030 |
Why?
|
| Dietary Fats | 1 | 1996 | 130 | 0.030 |
Why?
|
| Hydroxyurea | 1 | 1995 | 30 | 0.030 |
Why?
|
| Cell-Free System | 2 | 1992 | 12 | 0.030 |
Why?
|
| NFATC Transcription Factors | 1 | 2014 | 23 | 0.030 |
Why?
|
| Movement | 1 | 1995 | 82 | 0.030 |
Why?
|
| Carotid Arteries | 1 | 2015 | 77 | 0.030 |
Why?
|
| Plaque, Atherosclerotic | 1 | 2015 | 44 | 0.030 |
Why?
|
| Acylation | 1 | 1994 | 8 | 0.030 |
Why?
|
| Glutathione | 1 | 2015 | 305 | 0.030 |
Why?
|
| Calcium-Transporting ATPases | 1 | 1994 | 13 | 0.030 |
Why?
|
| Sarcoplasmic Reticulum | 1 | 1994 | 22 | 0.030 |
Why?
|
| Peptides | 1 | 1995 | 223 | 0.030 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2014 | 25 | 0.030 |
Why?
|
| Bone and Bones | 1 | 2018 | 494 | 0.030 |
Why?
|
| Calcineurin | 1 | 2014 | 72 | 0.030 |
Why?
|
| Genetic Complementation Test | 1 | 1993 | 47 | 0.030 |
Why?
|
| Neoplasm Staging | 1 | 2016 | 772 | 0.030 |
Why?
|
| Subcellular Fractions | 2 | 2005 | 34 | 0.030 |
Why?
|
| Tetradecanoylphorbol Acetate | 2 | 1996 | 46 | 0.030 |
Why?
|
| Glucose | 1 | 2015 | 355 | 0.030 |
Why?
|
| Neoplasm Transplantation | 2 | 2009 | 87 | 0.030 |
Why?
|
| Ethanolamine | 1 | 1992 | 2 | 0.030 |
Why?
|
| Trypanosoma | 1 | 1992 | 2 | 0.030 |
Why?
|
| Chromatography, Ion Exchange | 1 | 1992 | 16 | 0.030 |
Why?
|
| Hexosamines | 1 | 1992 | 2 | 0.030 |
Why?
|
| Chromatography, Gel | 1 | 1992 | 40 | 0.030 |
Why?
|
| Kruppel-Like Transcription Factors | 1 | 2013 | 36 | 0.030 |
Why?
|
| Aminoacyltransferases | 1 | 1992 | 1 | 0.020 |
Why?
|
| Cell Growth Processes | 1 | 2012 | 22 | 0.020 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2013 | 78 | 0.020 |
Why?
|
| Phenotype | 2 | 1986 | 789 | 0.020 |
Why?
|
| Glucosamine | 1 | 1992 | 9 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2014 | 483 | 0.020 |
Why?
|
| Phosphoinositide Phospholipase C | 1 | 1992 | 4 | 0.020 |
Why?
|
| Smoking | 1 | 2016 | 520 | 0.020 |
Why?
|
| Inositol | 1 | 1992 | 19 | 0.020 |
Why?
|
| Phospholipase D | 1 | 1992 | 11 | 0.020 |
Why?
|
| Extracellular Matrix | 1 | 2013 | 112 | 0.020 |
Why?
|
| Patient Selection | 1 | 2014 | 259 | 0.020 |
Why?
|
| Lysine | 2 | 2005 | 89 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2013 | 220 | 0.020 |
Why?
|
| I-kappa B Kinase | 1 | 2011 | 20 | 0.020 |
Why?
|
| Autoradiography | 1 | 1991 | 32 | 0.020 |
Why?
|
| Co-Repressor Proteins | 2 | 2003 | 18 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1991 | 96 | 0.020 |
Why?
|
| Alternative Splicing | 2 | 2003 | 62 | 0.020 |
Why?
|
| Ca(2+) Mg(2+)-ATPase | 1 | 1991 | 2 | 0.020 |
Why?
|
| Dynamins | 1 | 1991 | 9 | 0.020 |
Why?
|
| Prodrugs | 1 | 2011 | 35 | 0.020 |
Why?
|
| Spores, Fungal | 1 | 1991 | 21 | 0.020 |
Why?
|
| Open Reading Frames | 1 | 1991 | 55 | 0.020 |
Why?
|
| Aluminum Compounds | 1 | 1990 | 3 | 0.020 |
Why?
|
| Enzyme Stability | 1 | 2010 | 21 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2014 | 706 | 0.020 |
Why?
|
| Vesicular Transport Proteins | 1 | 1991 | 38 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2010 | 48 | 0.020 |
Why?
|
| Response Elements | 1 | 2010 | 29 | 0.020 |
Why?
|
| Cysteine | 1 | 2010 | 49 | 0.020 |
Why?
|
| Neoplasms, Experimental | 1 | 1991 | 114 | 0.020 |
Why?
|
| Kidney Glomerulus | 1 | 2010 | 41 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 137 | 0.020 |
Why?
|
| Radioactive Fallout | 1 | 2010 | 3 | 0.020 |
Why?
|
| Genetic Therapy | 1 | 2011 | 121 | 0.020 |
Why?
|
| Glioma | 1 | 1991 | 78 | 0.020 |
Why?
|
| NIH 3T3 Cells | 1 | 2010 | 51 | 0.020 |
Why?
|
| Oxidants | 1 | 2010 | 51 | 0.020 |
Why?
|
| Cricetinae | 2 | 2005 | 194 | 0.020 |
Why?
|
| Pericarditis | 1 | 2010 | 20 | 0.020 |
Why?
|
| Gene Knockdown Techniques | 1 | 2010 | 108 | 0.020 |
Why?
|
| Hodgkin Disease | 1 | 2010 | 49 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 120 | 0.020 |
Why?
|
| Models, Animal | 1 | 2010 | 234 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2010 | 255 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2009 | 15 | 0.020 |
Why?
|
| Least-Squares Analysis | 1 | 2009 | 44 | 0.020 |
Why?
|
| Occupational Exposure | 1 | 2010 | 111 | 0.020 |
Why?
|
| Injections | 1 | 2008 | 61 | 0.020 |
Why?
|
| Immunosorbent Techniques | 1 | 1988 | 4 | 0.020 |
Why?
|
| Calcimycin | 1 | 1988 | 6 | 0.020 |
Why?
|
| Membrane Lipids | 1 | 1988 | 13 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 2008 | 163 | 0.020 |
Why?
|
| Clone Cells | 1 | 1988 | 77 | 0.020 |
Why?
|
| Receptors, Interleukin-2 | 1 | 1987 | 7 | 0.020 |
Why?
|
| Dogs | 2 | 2000 | 180 | 0.020 |
Why?
|
| Lymphokines | 1 | 1987 | 20 | 0.020 |
Why?
|
| Cross-Linking Reagents | 1 | 1987 | 43 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2009 | 713 | 0.020 |
Why?
|
| Receptors, Immunologic | 1 | 1987 | 39 | 0.020 |
Why?
|
| Structure-Activity Relationship | 1 | 1988 | 404 | 0.020 |
Why?
|
| Lymphocyte Culture Test, Mixed | 1 | 1986 | 7 | 0.020 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1986 | 58 | 0.020 |
Why?
|
| Nuclear Export Signals | 1 | 2006 | 2 | 0.020 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 1986 | 66 | 0.020 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1986 | 43 | 0.020 |
Why?
|
| H-2 Antigens | 1 | 1986 | 4 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1986 | 122 | 0.020 |
Why?
|
| Intracranial Embolism | 1 | 2006 | 29 | 0.020 |
Why?
|
| Hydrolases | 1 | 2005 | 5 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 405 | 0.020 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2005 | 10 | 0.020 |
Why?
|
| Echocardiography, Transesophageal | 1 | 2006 | 60 | 0.020 |
Why?
|
| Complement Activation | 1 | 2005 | 24 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 2005 | 42 | 0.020 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2005 | 49 | 0.010 |
Why?
|
| Glycine | 1 | 2005 | 75 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2005 | 102 | 0.010 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 86 | 0.010 |
Why?
|
| Mice, Inbred A | 1 | 1984 | 15 | 0.010 |
Why?
|
| Escherichia coli | 1 | 1986 | 192 | 0.010 |
Why?
|
| Mice, Inbred DBA | 1 | 1984 | 47 | 0.010 |
Why?
|
| Genotype | 1 | 1986 | 566 | 0.010 |
Why?
|
| Viral Proteins | 1 | 2005 | 164 | 0.010 |
Why?
|
| Polymorphism, Genetic | 1 | 1984 | 185 | 0.010 |
Why?
|
| Testis | 1 | 2004 | 72 | 0.010 |
Why?
|
| Cadmium | 1 | 2003 | 21 | 0.010 |
Why?
|
| Macromolecular Substances | 1 | 2003 | 31 | 0.010 |
Why?
|
| DNA Mutational Analysis | 1 | 2003 | 180 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 2006 | 285 | 0.010 |
Why?
|
| HSP70 Heat-Shock Proteins | 1 | 2003 | 61 | 0.010 |
Why?
|
| Echocardiography | 1 | 2006 | 415 | 0.010 |
Why?
|
| Leucine | 1 | 2003 | 114 | 0.010 |
Why?
|
| Staphylococcus aureus | 1 | 2006 | 338 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2003 | 121 | 0.010 |
Why?
|
| Chemokine CCL5 | 1 | 2001 | 9 | 0.010 |
Why?
|
| Simvastatin | 1 | 2001 | 29 | 0.010 |
Why?
|
| Fenofibrate | 1 | 2001 | 17 | 0.010 |
Why?
|
| L-Selectin | 1 | 2000 | 7 | 0.010 |
Why?
|
| Phenyl Ethers | 1 | 2000 | 5 | 0.010 |
Why?
|
| Neutralization Tests | 1 | 2000 | 27 | 0.010 |
Why?
|
| Blood Cell Count | 1 | 2000 | 37 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 138 | 0.010 |
Why?
|
| Platelet Aggregation | 1 | 2000 | 72 | 0.010 |
Why?
|
| Leukocytes | 1 | 2000 | 66 | 0.010 |
Why?
|
| Helix-Loop-Helix Motifs | 1 | 2000 | 3 | 0.010 |
Why?
|
| Rad52 DNA Repair and Recombination Protein | 1 | 1999 | 3 | 0.010 |
Why?
|
| Conserved Sequence | 1 | 1999 | 53 | 0.010 |
Why?
|
| Type C Phospholipases | 2 | 1990 | 12 | 0.010 |
Why?
|
| Selection, Genetic | 1 | 1998 | 28 | 0.010 |
Why?
|
| Gene Deletion | 1 | 1999 | 272 | 0.010 |
Why?
|
| Viper Venoms | 1 | 1997 | 7 | 0.010 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 1997 | 12 | 0.010 |
Why?
|
| United States | 1 | 2009 | 5192 | 0.010 |
Why?
|
| Nitric Oxide Synthase | 1 | 1997 | 62 | 0.010 |
Why?
|
| Peptides, Cyclic | 1 | 1997 | 42 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 1997 | 93 | 0.010 |
Why?
|
| Rats, Wistar | 1 | 1997 | 193 | 0.010 |
Why?
|
| Oligopeptides | 1 | 1997 | 92 | 0.010 |
Why?
|
| Piperidines | 1 | 1997 | 97 | 0.010 |
Why?
|
| Vasoconstrictor Agents | 1 | 1997 | 82 | 0.010 |
Why?
|
| Blood Coagulation | 1 | 1997 | 64 | 0.010 |
Why?
|
| Phospholipids | 1 | 1996 | 59 | 0.010 |
Why?
|
| Crossing Over, Genetic | 1 | 1994 | 8 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 1994 | 74 | 0.010 |
Why?
|
| Lymphocytes | 1 | 1994 | 153 | 0.010 |
Why?
|
| Tunicamycin | 1 | 1992 | 11 | 0.010 |
Why?
|
| Oligosaccharides | 1 | 1992 | 34 | 0.010 |
Why?
|
| Acyltransferases | 1 | 1992 | 25 | 0.010 |
Why?
|
| CHO Cells | 1 | 1992 | 125 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1992 | 94 | 0.010 |
Why?
|
| Endoplasmic Reticulum | 1 | 1992 | 111 | 0.010 |
Why?
|
| Concanavalin A | 1 | 1991 | 11 | 0.010 |
Why?
|
| Kinetics | 1 | 1992 | 626 | 0.010 |
Why?
|
| Receptors, Mitogen | 1 | 1990 | 1 | 0.010 |
Why?
|
| Fluorides | 1 | 1990 | 3 | 0.010 |
Why?
|
| Ethyl Methanesulfonate | 1 | 1990 | 6 | 0.010 |
Why?
|
| Aluminum | 1 | 1990 | 12 | 0.010 |
Why?
|
| Phosphatidylinositol 4,5-Diphosphate | 1 | 1990 | 11 | 0.010 |
Why?
|
| Placenta | 1 | 1992 | 153 | 0.010 |
Why?
|
| Mutagenesis | 1 | 1990 | 61 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 1991 | 116 | 0.010 |
Why?
|
| Kidney | 1 | 1992 | 707 | 0.000 |
Why?
|
| Thymoma | 1 | 1986 | 12 | 0.000 |
Why?
|
| Antigen-Antibody Reactions | 1 | 1986 | 15 | 0.000 |
Why?
|
| Antigen-Presenting Cells | 1 | 1986 | 23 | 0.000 |
Why?
|
| Mice, Inbred Strains | 1 | 1986 | 163 | 0.000 |
Why?
|
| Bone Marrow | 1 | 1986 | 364 | 0.000 |
Why?
|